Travere Therapeutics (TVTX) Cash & Equivalents (2013 - 2026)
Travere Therapeutics posted quarterly Cash & Equivalents of $78.4 million for Q1 2026, up 26.6% year-on-year from $61.9 million in Q1 2025, and down 15.77% on a QoQ basis from $93.0 million in Q4 2025.
Travere Therapeutics (TVTX) has 14 years of Cash & Equivalents data on file, last reported at $78.4 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents rose 26.6% year-over-year to $78.4 million; the trailing twelve-month figure through Mar 2026 stood at $78.4 million (up 26.6% YoY), and the FY2025 full-year result was $93.0 million, up 58.94% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $78.4 million, down from $93.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $256.6 million in Q1 2022 and bottomed at $32.3 million in Q2 2024.
- The 5-year median for Cash & Equivalents is $75.2 million (2025), against an average of $98.5 million.
- The widest annual swing landed in 2024, when Cash & Equivalents tumbled 74.76%; it then jumped 204.68% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $61.7 million in 2022, then retreated by 5.69% to $58.2 million in 2023, then advanced by 0.62% to $58.5 million in 2024, then surged by 58.94% to $93.0 million in 2025, then slipped by 15.77% to $78.4 million in 2026.
- The last three Cash & Equivalents figures came in at $78.4 million (Q1 2026), $93.0 million (Q4 2025), and $110.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | 78.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.36 Mn |
| Dec 31, 2025 | 93.04 Mn |
| Sep 30, 2025 | 110.93 Mn |
| Jun 30, 2025 | 75.15 Mn |
| Mar 31, 2025 | 61.90 Mn |
| Dec 31, 2024 | 58.54 Mn |
| Sep 30, 2024 | 36.41 Mn |
| Jun 30, 2024 | 32.29 Mn |
| Mar 31, 2024 | 43.25 Mn |
| Dec 31, 2023 | 58.18 Mn |
| Sep 30, 2023 | 144.24 Mn |
| Jun 30, 2023 | 70.87 Mn |
| Mar 31, 2023 | 161.38 Mn |
| Dec 31, 2022 | 61.69 Mn |
| Sep 30, 2022 | 151.34 Mn |
| Jun 30, 2022 | 179.76 Mn |
| Mar 31, 2022 | 256.57 Mn |
| Dec 31, 2021 | 165.75 Mn |
| Sep 30, 2021 | 150.33 Mn |
| Jun 30, 2021 | 83.29 Mn |
| Mar 31, 2021 | 148.23 Mn |
| Dec 31, 2020 | 84.77 Mn |
| Sep 30, 2020 | 200.48 Mn |
| Jun 30, 2020 | 237.17 Mn |
| Mar 31, 2020 | 67.02 Mn |
| Dec 31, 2019 | 62.44 Mn |
| Sep 30, 2019 | 65.19 Mn |
| Jun 30, 2019 | 75.66 Mn |
| Mar 31, 2019 | 69.84 Mn |
| Dec 31, 2018 | 102.87 Mn |
| Sep 30, 2018 | 154.82 Mn |
| Jun 30, 2018 | 89.31 Mn |
| Mar 31, 2018 | 61.12 Mn |
| Dec 31, 2017 | 99.39 Mn |
| Sep 30, 2017 | 98.99 Mn |
| Jun 30, 2017 | 89.27 Mn |
| Mar 31, 2017 | 41.87 Mn |
| Dec 31, 2016 | 41.00 Mn |
| Sep 30, 2016 | 23.90 Mn |
| Jun 30, 2016 | 21.16 Mn |
| Mar 31, 2016 | 23.26 Mn |
| Dec 31, 2015 | 37.81 Mn |
| Sep 30, 2015 | 140.60 Mn |
| Jun 30, 2015 | 127.75 Mn |
| Mar 31, 2015 | 120.18 Mn |
| Dec 31, 2014 | 18.20 Mn |
| Sep 30, 2014 | 25.86 Mn |
| Jun 30, 2014 | 39.88 Mn |
| Mar 31, 2014 | 3.70 Mn |
| Dec 31, 2013 | 6.00 Mn |
| Sep 30, 2013 | 13.41 Mn |